Related references
Note: Only part of the references are listed.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
Steven J. Isakoff et al.
FUTURE ONCOLOGY (2017)
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Mark E. Robson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew et al.
BRITISH JOURNAL OF CANCER (2016)
Genetics of triple-negative breast cancer: Implications for patient care
Anosheh Afghahi et al.
CURRENT PROBLEMS IN CANCER (2016)
Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey
G. Cecener et al.
MOLECULAR BIOLOGY REPORTS (2016)
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Karolina N. Dziadkowiec et al.
MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
PARP inhibitors in the management of breast cancer: current data and future prospects
Luca Livraghi et al.
BMC MEDICINE (2015)
Triple positive breast cancer: A distinct subtype?
Patrizia Vici et al.
CANCER TREATMENT REVIEWS (2015)
Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
Shannon Leigh Huggins-Puhalla et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Fergus J. Couch et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Triple-negative breast cancer: new perspectives for targeted therapies
Federica Tomao et al.
ONCOTARGETS AND THERAPY (2015)
Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
Vandana G. Abramson et al.
CANCER (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Triple-Negative Breast Carcinoma Current and Emerging Concepts
Robert Schmadeka et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Triple Negative Breast Cancer
Idil Cetin et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
BRCA1/2 Germline Mutations and Their Clinical Importance in Turkish Breast Cancer Patients
Gulsah Cecener et al.
CANCER INVESTIGATION (2014)
Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
Amir Sonnenblick et al.
CANCER TREATMENT REVIEWS (2014)
Triple-negative breast cancer: future prospects in diagnosis and management
Shereef Elsamany et al.
MEDICAL ONCOLOGY (2014)
The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China
Yong Tao Li et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2014)
Systemic treatment strategies for triple-negative breast cancer
Budhi Singh Yadav et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Olav Engebraaten et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Rachel Greenup et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
Roxana Chiorean et al.
BREAST (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Updates in the treatment of basal/triple-negative breast cancer
Mythili Shastry et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2013)
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
Valentina Guarneri et al.
DRUGS (2013)
Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer
Haeyoung Kim et al.
JOURNAL OF BREAST CANCER (2013)
A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
Fatemeh Karami et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
Silvana B. De Lorenzo et al.
FRONTIERS IN ONCOLOGY (2013)
Emerging targeted therapies in triple-negative breast cancer
J. Crown et al.
ANNALS OF ONCOLOGY (2012)
Targeting triple-negative breast cancer: optimising therapeutic outcomes
K. Gelmon et al.
ANNALS OF ONCOLOGY (2012)
Targeted therapy for triple-negative breast cancer: Where are we?
Michael J. Duffy et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?
D. Gareth Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A snapshot of chemoresistance to PARP inhibitors
Alberto Chiarugi
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Soley Bayraktar et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women
Eunjung Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement
Alan Mackay et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
M. Javle et al.
Therapeutic Advances in Medical Oncology (2011)
Management Options in Triple-Negative Breast Cancer
Christina A. Minami et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2011)
Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients
Esra Manguoglu et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
Antonis C. Antoniou et al.
CANCER RESEARCH (2010)
Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
Treatment options for patients with triple-negative breast cancer
Rafael Santana-Davila et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Triple-negative breast cancer: Present challenges and new perspectives
Franca Podo et al.
MOLECULAR ONCOLOGY (2010)
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
Bryan P. Rowe et al.
BREAST CANCER RESEARCH (2010)
Triple-negative breast cancer
Reinaldo D. Chacon et al.
BREAST CANCER RESEARCH (2010)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
Triple-negative breast cancer-current status and future directions
O. Gluz et al.
ANNALS OF ONCOLOGY (2009)
BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer
Michael J. Hall et al.
CANCER (2009)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Pharmacotherapy of triple-negative breast cancer
Cagatay Arslan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Triple-negative breast cancer: Novel therapies and new directions
Sumanta Kumar Pal et al.
MATURITAS (2009)
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Yvette Drew et al.
RECENT ADVANCES IN CLINICAL ONCOLOGY (2008)
Targeted therapy for cancer using PARP inhibitors
Christopher J. Lord et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
What is triple-negative breast cancer?
William J. Irvin et al.
EUROPEAN JOURNAL OF CANCER (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
BRCA1 dysfunction in sporadic basal-like breast cancer
N. C. Turner et al.
ONCOGENE (2007)
Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives
Unal Egeli et al.
CANCER INVESTIGATION (2006)
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2005)
Hereditary breast cancer syndromes in a Turkish population.: Results of molecular germline analysis
S Güran et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
ME Robson et al.
BREAST CANCER RESEARCH (2004)
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
WD Foulkes et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Germline Mutations in the BRCA1 and BRCA2 Genes in Turkish Breast/Ovarian Cancer Patients
A. Esra Manguoglu et al.
HUMAN MUTATION (2003)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients
H Özdag et al.
EUROPEAN JOURNAL OF CANCER (2000)
BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients
H Yazici et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
